PTPA and Cognitive impairment: Cognitive impairment driven by amyloid β aggregates was reduced following treatment of animals with the novel PP2A-activating compound EHT (Asam et al., 2017; Basurto-Islas et al., 2014) or FTY720 (Asle-Rousta, Kolahdooz, Dargahi, Ahmadiani, & Nasoohi, 2014; Asle-Rousta, Kolahdooz, Oryan, Ahmadiani, & Dargahi, 2013; Hemmati et al., 2013).